Mazdutide

Synonyms: BI 456906, GLP-1/Glucagon receptor agonist, 2259884-03-0

Mazdutide is a synthetic peptide dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Innovent Biologics in partnership with Eli Lilly, it is currently in clinical development for the treatment of type 2 diabetes and obesity. The peptide combines the glucose-lowering effects of GLP-1 with the energy-expending effects of glucagon, offering a promising approach to addressing metabolic disorders.

Produkt-Highlights

• Dual agonist activity: Simultaneously activates GLP-1 and glucagon receptors for enhanced metabolic benefits.
• High purity: ≥98% as determined by HPLC, ensuring reliable and reproducible results.
• Research-grade quality: Manufactured under strict quality control, with comprehensive COA and MSDS provided.
• Custom packaging: Available in various sizes to meet different research needs.
• Technischer Support: Our team of experts is available to assist with any questions regarding handling or storage.

Anwendungen

• Metabolic disease research, including type 2 diabetes and obesity.
• Studies on GLP-1 and glucagon receptor signaling pathways.
• Development of novel therapeutic peptides for metabolic disorders.

Technische Daten

Bestellung und Lieferung

• Verpackung: 5 g, 10 g, 50 g, 100 g, or customized
• Mindestbestellmenge: 5 g
• Lieferzeit: 1-2 weeks after order confirmation
• Dokumentation: COA, MSDS, TDS provided

Angebotsanfrage

• Unsere Adresse: 280 Main Street, Xi’an, Shaanxi, China
• LyvBio GmbH. — E-Mail: info@lyvbio.com